Featured Courses

Examining the Clinical Potential of PARP Inhibitors in Prostate Cancer

AMA PRA Category 1 Credit(s)^TM

The advent of poly-(ADP ribose)-polymerase (PARP) inhibitors for a variety of malignancies has led to the evaluation of their use in patients with metastatic castrate resistant prostate cancer (mCRPC), and has the potential to shift treatment paradigms for these patients.

Sorting Out the Androgen Deprivation Therapy Options for Locally Advanced CSPC

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s), ABIM MOC Points, CE for Pharmacists, AAPA Category I CME credit

This CMEOCast episode will aim to improve knowledge and competence in integrating the latest data on the management of patients with early-stage prostate cancer by evaluating strategies for its management and differentiating the potential for adverse effects between androgen deprivation therapies.

NEJM Knowledge+ Pain Management and Opioids | myCME

AMA PRA Category 1 Credit(s)^TM, ABIM MOC Points, AAPA Category I CME credit, CE for Pharmacists, AANP Contact Hour(s), AAFP Prescribed Credit

10.00 CME CPE: Relevant case-based questions and feedback and high-yield resources to enhance opioid knowledge and prescribing confidence. Exp 10/27/22

Caring for Patients with Relapsed or Refractory MM | myCME

ANCC Contact Hour(s), IPCE Credit(s)

1.00 CE: Cleveland Clinic’s Dr. Beth Faiman discusses MM treatment with the goal of keeping patients on therapy and maintaining their QOL. Exp 4/29/23

Treatment Options & Clinical Dilemmas in Biochemical Recurrence

AMA PRA Category 1 Credit(s)^TM, ABIM MOC Points, CE for Pharmacists

This CME Outfitters podcast will focus on how clinicians can individualize treatment decisions, based on the use of risk assessment algorithms and advanced imaging techniques with greater ability to detect the sites and extent of disease at BCR.

Treating Patients with BRAF-Mutant or MSI-H mCRC | myCME

AMA PRA Category 1 Credit(s)^TM

0.75 AMA credits. Leading expert Dr. Dung Le discusses biomarker testing, treatment selection, and mitigating potential adverse events. Exp. 10/12/22.

Checkpoint Inhibitor Therapy and Manifestations of irAEs | myCME

AMA PRA Category 1 Credit(s)^TM, AAPA Category I CME credit, ANCC Contact Hour(s)

0.50 CME/CE: Dr. Aung Naing provides an overview of modifications to immunotherapy regimen associated with checkpoint inhibitor therapy. Exp 12/15/22

Treating NTRK Fusion–Positive Colorectal Cancer | myCME

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s)

0.50 CME/CE: In this activity, faculty will explore current actionable biomarkers and best practices for identifying NTRK fusions. Exp 1/31/23

Update on the Complexities of Follicular Lymphoma | myCME

AAPA Category I CME credit, ANCC Contact Hour(s), IPCE Credit(s)

1.00 CME CE: Offers expert strategies for managing patients with relapsed/refractory FL using clinical trial data along with real-world anecdotes. Exp 8/16/22

Optimizing Use of Checkpoint Inhibitors in NSCLC | myCME

AAPA Category I CME credit, ANCC Contact Hour(s), IPCE Credit(s)

1.00 CME CE: Reviews clinical trial data and provides expert insights on using immune checkpoint inhibitors for patients with NSCLC. Exp 8/16/22

Novel Targets for Higher-risk Myelodysplastic Syndromes | myCME

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s), CE for Pharmacists

1.00 CME CE: Highlights clinical data supporting the importance of differential diagnosis, risk stratification, and emerging therapies. Exp 2/24/23

Endometrial Cancer Treatment and Outcomes | myCME

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s), CE for Pharmacists

1.00 CME: Experts debate and discuss molecular testing, clinical data, treatment selection, and patient management in endometrial cancer. Exp 2/24/23